Ionis Pharmaceuticals (IONS) Stock Price, Quote & News

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult pat...

Industry: Biotechnology

Sector: Healthcare

Phone: 760 931 9200

Website: www.ionis.com

Address:

2855 Gazelle Court, Carlsbad, United States

Quantumup Jul. 23 at 2:57 PM

Morgan Stanley⬆️ $ARWR's PT to $120 (was $100),⬆️odds of success on plozasiran in severe hypertriglyceridemia (sHTG) to 90% from 75% and reiterated at Overweight after ARWR reported positive data from the Ph 3 SHASTA-3/4 studies. $IONS $LLY CRSP REGN AMRN

0 · Reply

trader_q Jul. 23 at 2:06 PM

$IONS going much higher $60 on deck. Gl all.

0 · Reply

BiodegradableBurger Jul. 23 at 1:58 PM

$IONS I don’t see any news.

0 · Reply

chartistmind Jul. 23 at 1:53 PM

$IONS would be even better if i stole some at 47. But they had to pull that move while i’m sleeping. Thieves.

0 · Reply

Quantumup Jul. 23 at 11:20 AM

H.C. Wainwright y'day reiterated $ARWR Buy-$100 and said -- Positive SHASTA-3 and SHASTA-4 topline readouts de-risk plozasiran's expansion into the much larger severe hypertriglyceridemia (sHTG) population. $IONS $RHHBY Here's what else H.C. Wainwright said inits note to investors: https://x.com/Quantumup1/status/2080251239028207906?s=20

0 · Reply

SuperGreenToday Jul. 23 at 3:52 AM

$IONS Share Price: $54.02 Contract Selected: Jan 15, 2027 $55 Calls Buy Zone: $5.02 – $6.20 Target Zone: $9.36 – $11.44 Potential Upside: 76% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Quantumup Jul. 22 at 7:23 PM

Chardan⬆️Top Pick $ARWR's PT to $115 from $90 &reit'd Buy after the Co reported that both the SHASTA-3 and SHASTA-4 Ph3 studies of plozasiran in sHTG met their 1° Endpoint—these data confirm the central pillar thesis that plozasiran delivers BiC efficacy and safety. $IONS $RHHBY

0 · Reply

chartistmind Jul. 22 at 5:57 PM

$IONS who stole some this morning?

1 · Reply

Biotechinves Jul. 22 at 3:58 PM

$IONS 10% down then up again. All dumped shares have been absorbed.

0 · Reply

chartistmind Jul. 22 at 2:35 PM

$IONS 47? ain’t fair, i was sleeping. People in east coast have an edge in this market over others.

1 · Reply

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

2026-07-21T12:06:09.000Z - 2 days ago

Ionis Pharmaceuticals price target lowered to $89 from $106 at Guggenheim

2026-07-15T21:25:30.000Z - 8 days ago

Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data

AMGN

2026-07-15T21:15:17.000Z - 8 days ago

Ionis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research

Jul 15, 2026, 4:02 PM EDT - 8 days ago

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS

Jul 15, 2026, 7:05 AM EDT - 8 days ago

Ionis to hold second quarter 2026 financial results webcast

2026-07-14T13:25:19.000Z - 9 days ago

Ionis says Biogen presents Phase 2 CELIA data at AAIC

BIIB

Jul 14, 2026, 9:16 AM EDT - 9 days ago

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

2026-07-13T14:50:11.000Z - 10 days ago

Alnylam price target raised to $485 from $470 at H.C. Wainwright

ALNY AZN

2026-07-13T13:25:09.000Z - 10 days ago

Ionis Pharmaceuticals price target lowered to $85 from $100 at RBC Capital

2026-07-13T11:05:59.000Z - 10 days ago

Ionis Pharmaceuticals doses first participant in Phase 1-2 ASCEND study

Jul 13, 2026, 7:00 AM EDT - 10 days ago

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

2026-07-10T13:20:39.000Z - 13 days ago

H.C. Wainwright trims Ionis price target, says trial failure reaction ‘overdone’

2026-07-10T12:25:48.000Z - 13 days ago

Ionis Pharmaceuticals price target lowered to $110 from $130 at Morgan Stanley

2026-07-10T11:05:45.000Z - 13 days ago

Ionis Pharmaceuticals price target lowered to $95 from $110 at Canaccord

AZN

2026-07-10T10:45:09.000Z - 13 days ago

Ionis Pharmaceuticals price target lowered to $90 from $115 at Barclays

2026-07-10T09:55:10.000Z - 13 days ago

Ionis Pharmaceuticals price target lowered to $100 from $115 at Citi

AZN

2026-07-09T16:55:16.000Z - 14 days ago

Ionis Pharmaceuticals price target lowered to $90 from $113 at Jefferies

2026-07-09T16:40:18.000Z - 14 days ago

Ionis Pharmaceuticals price target lowered to $86 from $105 at Needham

AZN

Jul 9, 2026, 7:38 AM EDT - 14 days ago

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

ALNY AZN

Jul 9, 2026, 5:53 AM EDT - 14 days ago

Major drugmaker loses $27 billion in market value after failed trial

AZN

Jul 9, 2026, 2:12 AM EDT - 15 days ago

AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial

AZN

Jul 9, 2026, 2:00 AM EDT - 15 days ago

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

Jul 6, 2026, 7:00 AM EDT - 17 days ago

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

Jun 25, 2026, 2:59 AM EDT - 4 weeks ago

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

Jun 24, 2026, 3:30 PM EDT - 4 weeks ago

Ionis Pharmaceuticals Transcript: FDA announcement

Jun 24, 2026, 3:30 PM EDT - 4 weeks ago

Ionis Pharmaceuticals Slides: FDA announcement

Jun 24, 2026, 3:30 PM EDT - 4 weeks ago

Ionis Pharmaceuticals Press release: FDA announcement

Jun 24, 2026, 2:37 PM EDT - 4 weeks ago

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

Jun 10, 2026, 8:40 AM EDT - 6 weeks ago

Ionis Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 8:40 AM EDT - 6 weeks ago

Ionis Pharmaceuticals Slides: FY 2026

Jun 8, 2026, 7:00 AM EDT - 6 weeks ago

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Jun 4, 2026, 5:30 PM EDT - 7 weeks ago

Ionis Pharmaceuticals Transcript: AGM 2026

Jun 4, 2026, 5:30 PM EDT - 7 weeks ago

Ionis Pharmaceuticals Slides: FY 2026

Jun 4, 2026, 7:00 AM EDT - 7 weeks ago

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

May 28, 2026, 4:45 AM EDT - 2 months ago

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

May 19, 2026, 8:30 AM EDT - 2 months ago

Ionis Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 14, 2026, 7:05 AM EDT - 2 months ago

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

May 12, 2026, 1:40 PM EDT - 2 months ago

Ionis Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 4, 2026, 7:05 AM EDT - 2 months ago

Ionis to host 2026 virtual Annual Meeting of Stockholders

May 1, 2026, 7:05 AM EDT - 2 months ago

Ionis to present at upcoming investor conferences

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Ionis Pharmaceuticals Earnings release: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Ionis Pharmaceuticals Slides: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Ionis Pharmaceuticals Quarterly report: Q1 2026

Apr 29, 2026, 7:00 AM EDT - 3 months ago

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Apr 28, 2026, 2:06 AM EDT - 3 months ago

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Ionis Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Ionis Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 7:00 AM EDT - 3 months ago

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Apr 15, 2026, 7:05 AM EDT - 3 months ago

Ionis to hold first quarter 2026 financial results webcast

Mar 30, 2026, 7:30 AM EDT - 4 months ago

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

BIIB

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

Mar 17, 2026, 12:00 PM EDT - 4 months ago

Ionis Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 1:30 PM EDT - 4 months ago

Ionis Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 9, 2026, 3:40 PM EDT - 4 months ago

Ionis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Ionis announces changes to Board of Directors

Mar 5, 2026, 7:30 AM EST - 5 months ago

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

BIIB

Mar 2, 2026, 10:30 AM EST - 5 months ago

Ionis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 7:00 AM EST - 5 months ago

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

Feb 26, 2026, 12:00 PM EST - 5 months ago

Ionis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 7:00 AM EST - 5 months ago

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

Feb 25, 2026, 8:30 AM EST - 5 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:30 AM EST - 5 months ago

Ionis Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 8:30 AM EST - 5 months ago

Ionis Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 8:30 AM EST - 5 months ago

Ionis Pharmaceuticals Slides: Q4 2025

Feb 25, 2026, 7:00 AM EST - 5 months ago

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

Feb 17, 2026, 2:58 PM EST - 5 months ago

Ionis updates time for fourth quarter and full year 2025 financial results webcast

Feb 11, 2026, 7:05 AM EST - 5 months ago

Ionis to hold fourth quarter and full year 2025 financial results webcast

Jan 21, 2026, 7:00 AM EST - 6 months ago

DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

Jan 13, 2026, 11:15 AM EST - 6 months ago

Ionis Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 11:15 AM EST - 6 months ago

Ionis Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 6 months ago

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

Jan 7, 2026, 2:15 AM EST - 7 months ago

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Jan 6, 2026, 7:05 AM EST - 7 months ago

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 7:00 AM EST - 8 months ago

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

Dec 1, 2025, 7:00 AM EST - 8 months ago

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

Nov 18, 2025, 8:30 AM EST - 8 months ago

Ionis Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 14, 2025, 4:05 PM EST - 8 months ago

Biogen Completes Acquisition of Alcyone Therapeutics

BIIB

Nov 14, 2025, 7:00 AM EST - 8 months ago

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

Nov 13, 2025, 8:00 AM EST - 9 months ago

Ionis Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 12:39 AM EST - 9 months ago

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

Nov 11, 2025, 4:05 PM EST - 9 months ago

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

Nov 8, 2025, 3:00 PM EST - 9 months ago

Ionis Pharmaceuticals Transcript: Study Update

Nov 8, 2025, 3:00 PM EST - 9 months ago

Ionis Pharmaceuticals Slides: Study Update

Nov 8, 2025, 9:40 AM EST - 9 months ago

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

Nov 6, 2025, 8:00 AM EST - 9 months ago

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

Oct 29, 2025, 11:30 AM EDT - 9 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 29, 2025, 11:30 AM EDT - 9 months ago

Ionis Pharmaceuticals Quarterly report: Q3 2025

Oct 29, 2025, 11:30 AM EDT - 9 months ago

Ionis Pharmaceuticals Earnings release: Q3 2025

Oct 29, 2025, 11:30 AM EDT - 9 months ago

Ionis Pharmaceuticals Slides: Q3 2025

Oct 29, 2025, 7:00 AM EDT - 9 months ago

Ionis reports third quarter 2025 financial results and highlights progress on key programs

Oct 27, 2025, 7:00 AM EDT - 9 months ago

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

Oct 23, 2025, 2:10 PM EDT - 9 months ago

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

Quantumup Jul. 23 at 2:57 PM

0 · Reply

trader_q Jul. 23 at 2:06 PM

$IONS going much higher $60 on deck. Gl all.

0 · Reply

BiodegradableBurger Jul. 23 at 1:58 PM

$IONS I don’t see any news.

0 · Reply

chartistmind Jul. 23 at 1:53 PM

$IONS would be even better if i stole some at 47. But they had to pull that move while i’m sleeping. Thieves.

0 · Reply

Quantumup Jul. 23 at 11:20 AM

0 · Reply

SuperGreenToday Jul. 23 at 3:52 AM

0 · Reply

Quantumup Jul. 22 at 7:23 PM

0 · Reply

chartistmind Jul. 22 at 5:57 PM

$IONS who stole some this morning?

1 · Reply

Biotechinves Jul. 22 at 3:58 PM

$IONS 10% down then up again. All dumped shares have been absorbed.

0 · Reply

chartistmind Jul. 22 at 2:35 PM

$IONS 47? ain’t fair, i was sleeping. People in east coast have an edge in this market over others.

1 · Reply

johnnygogogo Jul. 22 at 12:55 PM

$IONS now we know why IONS insiders were selling so aggressively…

0 · Reply

skeezbag Jul. 22 at 12:00 PM

$ARWR now the lying CEO of $IONS can fade to black 100% AP reduction in high risk patients

1 · Reply

Pika_Capital Jul. 22 at 11:53 AM

$ARWR amazing data. No wonder $IONS is down

0 · Reply

roscoe44 Jul. 21 at 7:50 PM

$IONS There was huge bear bet here. Need to be careful either its fund hedging or someone knows earnings here. Anyway have very small position here.

1 · Reply

murphylaw Jul. 21 at 6:35 PM

$IONS should be $70 on July 29th after earnings. Also, this is top 5 company for a buyout given how cheap it is right now. you can probably buy for $125 a share. Bargain of a lifetime if I am a BP with no pipeline ( a la pfizer, novo nordisk, merck)

0 · Reply

JuggernautRaider Jul. 21 at 4:32 PM

$IONS IONIS WILL BE OVERSOLD AT SOME POINT

0 · Reply

djgestates Jul. 21 at 3:43 PM

$IONS

0 · Reply

chartistmind Jul. 20 at 3:44 PM

$IONS ok, in. starter here but I have to ask- bagholders wtf happened here?

1 · Reply

zoomlik Jul. 20 at 2:29 PM

$IONS Peak sales of hstg indication with ARWR data if as good, with once a 3 months but 1 year lag ?

0 · Reply

econometrics101 Jul. 19 at 11:40 PM

$IONS .

0 · Reply

Naraid Jul. 18 at 4:19 PM

$IONS Cathie Wood Just Bet Big on This Biotech Stock | The Motley Fool https://share.google/jgStgeOEggcd5PL0n

0 · Reply

JFais Jul. 17 at 4:05 PM

Trying to warm up to $IONS on the selloff, but red flag for me is that the CEO seems to dismiss competition from $ARWR's Redemplo at every turn Multiple calls, same theme (focusing on Tryngolza launch, not what others are doing) Respect the emphasis on execution, but still...

4 · Reply

Market Cap	8.93B
Revenue (ttm)	943.71M
Net Income (ttm)	-381.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-40.41%
Debt to Equity Ratio	0.00

Volume	3,834,300
Avg Vol	2,895,190
Day's Range	N/A - N/A
Shares Out	165.26M
Stochastic %K	74%
Beta	0.36
Analysts	Strong Sell
Price Target	$90.76